News
The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.
6h
Zacks.com on MSNMRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric PatientsModerna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to ...
Pfizer (PFE) and BioNTech (BNTX) challenge Moderna's patent win in London court over mRNA COVID-19 vaccine technology. Read ...
The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results